August 20, 2019 | 10 min. | On n’est pas obligé d’être d’accord (QUB Radio) Interview (in French) with Patrick Déry, Senior […]

Should we allow the importation of drugs from Canada into the United States?

July 23, 2019 | 11 min. 41 sec. | Midi Pile (KYK Radio) Interview (in French) with Patrick Déry, Senior Associate Analyst […]

May 16, 2019 | 39 min. 33 sec. | Isabelle (98,5 FM) Debate (in French) with Patrick Déry, Senior Public Policy Analyst […]

Health Canada’s reform of the pricing mechanism for new drugs could delay their introduction.

Interview (in French) with Mathieu Bédard, Economist at the MEI, about Health Canada’s reform of the pricing mechanism for new drugs and how it could delay their introduction. Broadcast on April 18, 2019, on the LCN Mario Dumont show.

Health Canada’s reform of the pricing mechanism for new drugs could delay their introduction.

The Canadian government is planning to change the way prices are set for new patented drugs and cut the maximum prices at which these drugs can be sold by up to 70%. But this reform could prove very costly for patients. If it goes forward and fails to take into account the adverse effects of reference pricing systems, which have been well documented by various international bodies, Canadians could see their access to new drugs slowed down or even compromised.

The defects and impediments inherent in a top-down bureaucratic health care system like Canada‘s.

The debate over the nationalization of drug insurance.